Carl Hull, Maravai LifeSciences CEO

As pock­ets fill with cash, Mar­a­vai spends $240M to en­sure pure mR­NA pro­duc­tion

A San Diego-based life sci­ences com­pa­ny is tak­ing over a long­time sup­pli­er and Cal­i­for­nia neigh­bor to boost the pu­ri­ty of its nu­cleotides and im­prove the man­u­fac­tur­ing process of mR­NA, as the boom calls for more de­mand.

Mar­a­vai Life­Sciences ac­quired My­Chem for $240 mil­lion cash in a move that CEO Carl Hull says will help ex­pand the com­pa­ny’s of­fer­ing of ther­a­peu­tics and vac­cines.

“The great thing for us is that it al­lows us to have bet­ter con­trol over our sup­ply chain, so that’s a ben­e­fit for us and for our cus­tomers, but it al­so al­lows us to of­fer more com­po­nents, more dif­fer­en­ti­at­ed prod­ucts to our cus­tomers,” he said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.